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Purpose: To study the prescription of oral analgesics for musculoskeletal pain by primary care 
physicians over a 5-year period in Sweden.
Design: A retrospective automatic database review of patient records at four primary health 
care centers. All prescriptions of NSAIDs, weak opioids, and coprescriptions of gastroprotect-
ing medications to patients with musculoskeletal were retrieved for the period January 1, 2004 
to November 11, 2008.
Results: A total of 27,067 prescriptions prescribed to 23,457 patients with musculoskeletal pain 
were analyzed. Of all prescriptions, NSAIDs were the most commonly prescribed analgesic 
comprising 79%, tramadol was the second most commonly prescribed analgesic comprising 
9%, codeine the third most (7%), and dextropropoxyphene the fourth (5%). The proportion of 
NSAIDs and weak opioids and the proportion of the different weak opioids prescribed showed 
no change over time. The proportion of nonselective and selective NSAIDs prescribed changed; 
Coxib prescriptions decreased from 9% to 4% of all analgesics prescribed in 2004–2007 with 
no change in 2008.
Conclusion: NSAIDs were found to be the dominant class of analgesic prescribed by primary 
care physicians to patients diagnosed as musculoskeletal pain. No change was observed in 
the proportion of NSAID and weak opioid prescription over the period studied. Prescription 
of selective Coxibs decreased and was less than 4% in 2008. The impact on gastrointestinal 
and cardiovascular adverse effects associated with the extensive prescription of NSAIDS for 
musculoskeletal pain warrants further analysis.
Keywords: nonsteroidal anti-inflammatory drugs, tramadol, codeine, dextropropoxyphene, 
primary care, pattern of use, pharmacoepidemiology
Introduction
Musculoskeletal pain is one of the most common complaints seen by primary care 
  physicians.1 Pain therapy consists of nonpharmacological and pharmacological parts.2 
The nonsteroidal anti-inflammatory agents (NSAIDs) have become increasingly 
popular as a second-line therapy.3–5 Today, there are a variety of NSAIDs available 
for prescription: traditional nonselective (tNSAIDs), and the more selective COX-II-
inhibitors (Coxibs). The analgesic effects of the different NSAIDs are more or less 
identical; however, the Coxibs are associated with a lower risk for upper gastroin-
testinal side effects.6 Thus, the Coxibs after their   introduction become an alternative 
to traditional NSAIDs in patients exhibiting risk for upper   gastrointestinal bleeding.   Journal of Pain Research 2010:3
Table 1 Demographics for the entire cohort studied from January 1, 2004 to November 11, 2008
2004 
(N = 2909)
2005 
(N = 4849)
2006 
(N = 6141)
2007 
(N = 5754)
2008 
(N = 3894)
Female, n (%) 1766 (60.7) 2862 (59.0) 3523 (57.4) 3307 (57.5) 2183 (56.1)
Male, n (%) 1143 (39.3) 1987 (41.0) 2618 (42.6) 2447 (42.5) 1711 (43.9)
Age, y
  Total
    Mean (SD) 50.8 (15.9) 51.5 (16.0) 51.8 (16.2) 52.1 (16.4) 52.4 (16.3)
    Median 51.0 51.0 52.0 52.0 52.0
    Min – max 18–95 18–96 18–101 18–102 18–98
  Female
    Mean (SD) 51.4 (16.0) 52.3 (16.1) 52.7 (16.3) 52.8 (16.6) 53.5 (16.3)
    Median 52.0 53.0 53.0 53.0 54.0
    Min – max 18–95 18–96 18–101 18–102 18–98
  Male
    Mean (SD) 50.0 (15.7) 50.4 (15.8) 50.6 (15.9) 51.0 (16.1) 50.9 (16.2)
    Median 49.0 50.0 50.0 51.0 50.0
    Min – max 18–93 18–91 18–92 18–93 18–94
Abbreviation: SD, standard deviation.
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The national pain guidelines   provided by the Swedish Council 
on Technology Assessment in Health Care supports prescrip-
tion of Coxibs as a cost-effective option in patients with a 
gastrointestinal risk.2–4
There is still a need for individual analysis regarding 
the risk of side effects including not only the upper but the 
entire gastrointestinal tract and the cardiovascular system.7–11 
The long-term use of NSAIDs warrants, however, an in-depth 
analysis of benefit vs risk on an individual basis.
The aim of this present study was to review the 
  prescription pattern of NSAID and weak opioid analgesics 
for the treatment of musculoskeletal pain by primary care 
physicians over a 5-year period with a focus on whether 
any changes could be detected due to the increasing aware-
ness of the risk for gastrointestinal and cardiovascular 
risks associated with the long-term systemic use of anti-
inflammatory drugs.
Study design
The study protocol was reviewed and approved by the 
local ethical review board. A retrospective, patient record 
analysis was performed by a specially designed database 
tool that   automatically reviews the records searching for all 
  diagnostic codes of musculoskeletal pain (ICD-10 codes) and 
  prescriptions codes (ATC-codes) for NSAIDs   (nonselective 
and selective Coxibs) and weak opioids   (tramadol, codeine, 
and dextropropoxyphene) were collected and analyzed. 
The case records for all patients seen by one of general 
practitioners,   primary care physician, working at four major 
primary care   centers in the Stockholm area, primary care 
centers of   Eriksberg, Curera Söder, Österåker, and Skogås, 
were reviewed from January 1, 2004 through November 11, 
2008.
All data were collected and stored in an anonymous 
database without any coupling to the individual patient; no 
further patient details were compiled or stored.
Statistics
Prescription pattern is presented in absolute numbers and 
proportion of prescriptions made.
The data are presented for the entire cohort; all 
  prescriptions and patients are further separated into adult 
patients aged 18–65 years and elderly patients older than 
65 years.
Post hoc analysis of annual proportion of prescriptions 
data was analyzed by Chi-square test; a P , 0.05 was con-
sidered statistically significant.
Results
A total of 27,067 prescriptions prescribed to 13,641 females 
(58%) and 9,906 males (42%) diagnosed as musculoskeletal 
pain were reviewed. On the basis of age, 20,800 prescriptions 
were made to adult patients and 6,267 to elderly patients.
Patients’ demographics are presented in Table 1.
There were no major differences in patient demograph-
ics or prescription routines between the four primary health 
care centers studied.
The entire cohort
NSAIDs were most commonly prescribed analgesic 
(79%–80%) without any change in proportion of   prescription 
over the 5-year period studied. Tramadol was the second Journal of Pain Research 2010:3
Table 2 Annual numbers of prescriptions for the entire patient 
cohort studied
2004 2005 2006 2007 2008 Total %
tNSAIDs 2,332 4,116 5,327 5,079 3,420 20,274 75
Coxibs 304 289 256 201 140 1190 4
Codeine 233 384 484 447 314 1862 7
Dextropropxyphene 164 261 314 306 164 1209 5
Tramadol 317 529 680 612 394 2532 9
All prescriptions 3,350 5,579 7,061 6,645 4,432 27,067 100
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most (9%) of all analgesics prescribed and comprised 
45% of weak opioid prescriptions without any change 
over time (44%–46%). Codeine, dextropropoxyphene, and 
  selective Coxibs were prescribed in 7%, 5%, and 4% of all 
  prescriptions analyzed (Table 2).
The proportion of NSAID and weak opioid prescriptions 
in the entire cohort studied did not change during the study 
period. Prescription of Coxibs decreased, however, between 
2004 and 2007 (11.5%–3.8%, P , 0.01) with no further 
change in 2007–2008 (3.9% of all NSAIDs prescribed). 
A small reduction in dextropropoxyphene prescriptions was 
seen: 23%–19% of weak opioid from 2004 to 2008. Annual 
numbers of prescriptions are presented in Table 2 and the 
proportion of prescriptions annually is shown in Figure 1.
Separation of prescription data  
into adults and elderly patients
When the prescription data were separated for adult patients 
and elderly patients, different prescription patterns were 
observed. NSAIDs were more commonly prescribed to adults 
compared with elderly patients and weak opioids more com-
monly to elderly patients (P , 0.05; Table 3). The proportion 
of Coxib out of all NSAIDs prescribed was higher among 
elderly 7% vs 3% (P , 0.05; see Table 4).
Prescription of dextropropoxyphene showed no change 
among adults but decreased among elderly, compensated by 
an increase in tramadol prescription (Table 4).
Discussion
Principal findings
We found NSAIDs to be commonly prescribed for 
  musculoskeletal pain, and the proportion of NSAIDs and 
weak opioids prescribed did not change during the 5-year 
study (2004–2008). The relative proportion of traditional, 
nonselective NSAIDs and Coxibs prescribed did, however, 
change: the prescription of traditional nonselective NSAIDs 
increased and selective Coxibs decreased during the first 
4 years   studied but with no change during 2007–2008. 
  Prescription of weak opioids was in general more common 
among elderly;   however, in this more vulnerable patient 
cohort, no major change in the proportion of NSAIDs and 
weak opioids was noticed over the time period studied.
Strengths and weaknesses of the study
The aim of the present survey was to study the   prescription 
pattern of NSAIDs and weak opioids to patients with 
  musculoskeletal pain by primary care physicians. A group of 
patients commonly seen and where the prescription should be 
considered not only taking the analgesic effect but also the 
risks for side effects and health economy into account.12 By 
the automatic data case record review technique used, a huge 
number of prescriptions could be analyzed. The   prescription 
pattern was seemingly similar between the four health 
care centers studied, presenting both urban and suburban 
  environments. It should be acknowledged that no   intervention 
was done; all data were collected retrospectively by an auto-
matic review of patient data records, and thus no doctor bias 
can by any means be expected. The pattern observed should 
reasonably present a balanced view of clinical   routine pre-
scription practice. The study design carries however limita-
Table  3  Proportion  of  NSAID  and  weak  opioid  prescription 
among entire cohort and when divided into adults and elderly for 
the 5-year study period
2004 2005 2006 2007 2008
All
  NSAIDs 79 79 79 79 80
  Weak opioids 21 21 21 21 20
  All prescriptions 3,350 5,579 7,061 6,645 4,432
Adults
  NSAIDs 80 82 82 83 83
  Weak opioids 18 18 18 17 17
  All prescriptions 2,548 4,221 5,410 5,152 3,469
Elderly
  NSAIDs 73 70 69 68 72
  Weak opioids 27 30 31 32 28
  All prescriptions 802 1,358 1,651 1,493 963
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Figure 1 Proportion of prescriptions from 2004 to 2008 for the entire cohort 
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tions. The information retrieved included merely   prescription 
information, and no information of comorbidity, concomitant 
medications, or occurrence of side effects was unfortunately 
collected. The data retrieved   consists only of prescribed 
medication by ATC code. We have no data about incidence 
and severity of any side effects, need for extra/emergent 
health care center consultations, and visits to the emergency 
department or admission to hospital.
Our findings may not be seen as unexpected. NSAIDs have 
become the mainstay of therapy for acute   musculoskeletal 
pain.2,3 NSAIDs are also commonly recommended as 
second-line therapy for pain associated with arthritis when 
paracetamol has been tested or is unable to provide adequate 
pain control.2–4 One should, however, acknowledge that we 
studied primary care physicians and musculoskeletal pain, 
in general, and not firmly defined diagnosis of arthrosis 
or arthritis. Similar studies about prescription pattern 
for musculoskeletal pain made in the United States and 
  Finland (  published in 2001 and 2004) showed variability in 
  prescription routines.13,14 Also the findings in a Norwegian 
survey showed huge variability in patient intake of anal-
gesics for musculoskeletal pain.15 These studies describe 
prescription of NSAID systemic, as well as topical, weak 
opioids, and also occasionally stronger opioids. The option 
for over-the-counter (OTC) medication should also be 
acknowledged.16 We did not retrieve anamnestic information, 
and we are, thus, not able to state to what extent our patients 
used OTC drugs. A more recent American survey showed 
similar findings to ours, ie, a common prescription routine of 
NSAIDs,17 and the proportion of Coxibs prescribed changed 
with a peak in 2001–2003 followed by a dramatic reduction 
during 2004. The Vioxx and Bextra retractions following 
identification of an increased incidence of cardiovascular 
event in 2004 and 2005 caused a major change in the will-
ingness to prescribe Coxibs.9,10 Our findings with respect to 
NSAID use is similar to that found in a nationwide study in 
Denmark describing the annual NSAID market.18 The use 
of NSAIDs is supported by many national guidelines and 
international reviews, but the awareness of the risk for side 
effects associated with NSAIDs and the selective Coxibs 
have promoted a focus on paracetamol as the baseline drug 
and provided the option for addition of weak opioids when 
greater analgesia is desired.19
The prescription pattern and compliance to prescribed med-
ication are intrigues parts of the pharmacological   management 
especially in more protracted pain, “chronic pain situations” 
such as musculoskeletal pain including arthrosis/arthritis. 
The benefit from the analgesics,   reduction of pain, must be 
evaluated against the risk for side effects in each individual 
patient.20 Cost is also becoming increasingly important, and in 
many countries, cheapest generic product is recommended in 
order to reduce direct drug costs. Cost considerations should, 
however, take into account not only the direct prescribed drug 
cost but also costs associated with coprescriptions in order to 
prevent or treat side effects and other resources needed, ie, any 
additional contacts with health care.21 We found a clear switch, 
increase in   prescription of nonselective NSAIDs and a reduc-
tion in   prescription of Coxibs. The impact of this change needs 
  further attention. The option of paracetamol, topical NSAIDs, 
and addition of low-dose strong opioid when needed should 
be considered an alternative.
Unanswered questions  
and future research
The aim of the present study was to review prescription pat-
tern and changes over time. Information about dose, dosing, 
and compliance to prescription was not analyzed. No outcome 
variables were included; thus, it is not possible to make any 
assessment of risk vs benefit from the prescribed medications. 
The risk for gastrointestinal events associated with NASID 
use is well recognized. The Coxibs were introduced in order to 
reduce the gastrointestinal risk and the clinical benefit has been 
well documented.6 The beneficial effects with regard to upper 
gastrointestinal events with the Coxib must, of course, be put 
into the perspective of the cardiovascular risks. It is, however, 
becoming increasingly obvious that the cardiovascular risk is 
Table 4 Proportion of prescriptions in adult patients and elderly 
patients over the 5 year period studied
2004 2005 2006 2007 2008
Adults (age, 18–65 y)
tNSAIDs 90 95 96 96.5 97
Coxibs 10 5 4 3,5 3
NSAIDs 100 100 100 100 100
No. of prescription 2,053 3,455 4,443 4,271 2,870
Codeine 34 34 34 34 38
Dextropropoxyphene 19 19 18 19 18
Tramadol 47 47 48 47 44
Weak opioids 100 100 100 100 100
No. of prescription 495 766 967 881 599
Elderly (age > 65 y)
tNSAIDs 82 89 93 95 93
Coxibs 18 11 7 5 7
NSAIDs 100 100 100 100 100
No. of prescription 583 950 1,140 1,009 690
Codeine 30 31 30 30 32
Dextropropoxyphene 32 27 28 28 21
Tramadol 38 41 42 41 47
Weak opioids 100 99 100 99 100
No. of prescription 219 408 511 484 273Journal of Pain Research
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not class related but differs between the different substances.22,23 
Further studies   analyzing the overall benefit vs risk and pain 
reduction,   incidence and severity of any gastrointestinal and 
cardiovascular side effects   associated with the change in the 
prescription ratio of traditional NSAIDs (with and without 
coprescribed gastroprotection) and Coxibs are warranted.
Summary and conclusion
Anti-inflammatory agents, NSAIDs, were by far the most 
commonly prescribed analgesic by family physicians for the 
treatment of musculoskeletal pain. Prescription of Coxibs 
decreased, however, from 2004 and is only prescribed to a 
low percentage (,4%). The overall proportion between weak 
opioids (tramadol, codeine, and dextropropoxyphene) and 
NSAIDs or the relative proportion of the different weak opioids 
did not change. Studies evaluating the impact of this extensive 
use of NSAIDs on the upper gastrointestinal, as well as lower, 
and cardiovascular side effects are thus warranted.
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